Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Nefiracetam

Nefiracetam
Nefiracetam (DM9384) are underway in Phase 2 trials. Nefiracetam, a GABAergic、 cholinergic、and monoaminergic neuronal system enhancer, is used for Ro 5-4864-induced convulsions.
Catalog No. T0169Cas No. 77191-36-7
Select Batch
Purity:100%
Contact us for more batch information
Resource Download

Nefiracetam

Catalog No. T0169Cas No. 77191-36-7
Nefiracetam (DM9384) are underway in Phase 2 trials. Nefiracetam, a GABAergic、 cholinergic、and monoaminergic neuronal system enhancer, is used for Ro 5-4864-induced convulsions.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
100 mg$35In Stock
200 mg$47In Stock
500 mg$76In Stock
1 mL x 10 mM (in DMSO)$29In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Nefiracetam"

Product Introduction

Bioactivity
Description
Nefiracetam (DM9384) are underway in Phase 2 trials. Nefiracetam, a GABAergic、 cholinergic、and monoaminergic neuronal system enhancer, is used for Ro 5-4864-induced convulsions.
In vitro
In DDY mice, Nefiracetam (>10 mg/kg) effectively inhibits convulsions induced by Ro 5-4864. Oral administration of Nefiracetam suppresses Ro 5-4864-induced seizures in EL mice. Administering Nefiracetam (1 time/day) prior to each training session facilitates the acquisition of avoidance responses.
In vivo
Nefiracetam, at low concentrations (0.01–0.1 μM), induces a transient inhibition of Ach-evoked currents, while at higher concentrations (1–10 μM), it provides a sustained enhancement of these currents. Specifically, 1 μM Nefiracetam doubles the long-lasting component of the calcium channel current without affecting the transient component. After a 10-minute treatment with Nefiracetam, Ach-induced current is reduced to 30% at 0.01 μM and 38% at 0.1 μM of the control levels. The compound interacts with the PKC pathway, augmenting the activity of nicotinic Ach receptors, thereby increasing the release of presynaptic glutamate, and leading to potentiation of synaptic transmission in the hippocampus. This mechanism may underlie cognitive enhancement elicited by Nefiracetam through its interaction with PKA and PKC pathways. In primary cultures of rat hippocampal neurons, Nefiracetam increases the ratio of nicotinic-sensitive excitatory postsynaptic currents. Moreover, in rat hippocampal slices in both the CA1 region and the dentate gyrus, Nefiracetam induces long-lasting synaptic potentiation, which can be inhibited by α-bungarotoxin and mecamylamine.
Kinase Assay
Assay of glutamate released: Hippocampal slices (400 μM) are prepared from the guinea pig brain using standard techniques. A slice is fixed on a pair of silver wire electrodes (10 Hz, 5 V, 0.1 ms in duration) at 1-minutes intervals for 10 minutes and submerged in 1 mL standard artificial cerebrospinal fluid (ACSF) (in mM: 125 mM NaCl, 5 mM KCl, 1.24 mM KH2PO4, 1.3 mM MgSO4, 2 mM CaCl2, 26 mM NaHCO3, and 10 mM glucose) oxygenated with 95% O2 and 5% CO2 at 36 °C in the presence and absence of tetrodotoxin (TTX) (0.5 μM). In a different set of experiments, electrical stimulation is applied to slices treated with Nefiracetam (1 μM) in the presence and absence of α-bungarotoxin (50 nM) or mecamylamine (3 μM). A 100 μL aliquot of the medium filtered with millipore filters (0.45 μM) is injected onto the cation-exchanger column of the autoanalyser to separate amino acids and the amount of glutamate released is calculated using known amino acid standard concentrations.
Cell Research
The injected oocytes are transferred to the recording chamber 24 to 48 hours after incubation and continuously superfused at room temperature (20 to 22 °C) in a standard frog Ringer's solution (115 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, and 5 mM HEPES, pH 7.0). Ca2+ -free extracellular solution consisted of 115 mM NaCl, 2 mM KCl, 5 mM MgCl2, 5 mM HEPES, and 1 mM EGTA, pH 7.0. To remove the effect of the muscarinic ACh receptor, 1 μM atropine is added to the extracellular solution. ACh-activated currents are recorded using two-electrode, voltage-clamp techniques. The currents are analyzed on a microcomputer using pClamp software. ACh is bath-applied to oocytes. Nefiracetam is dissolved in distilled water at 1 mM for stock solution and diluted into concentrations required with the extracellular solution. (Only for Reference)
AliasDM9384, DZL-221
Chemical Properties
Molecular Weight246.3
FormulaC14H18N2O2
Cas No.77191-36-7
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 70 mg/mL (284.21 mM), Sonication is recommended.
Ethanol: 24.6 mg/mL (100 mM)
Solution Preparation Table
Ethanol/DMSO
1mg5mg10mg50mg
1 mM4.0601 mL20.3004 mL40.6009 mL203.0045 mL
5 mM0.8120 mL4.0601 mL8.1202 mL40.6009 mL
10 mM0.4060 mL2.0300 mL4.0601 mL20.3004 mL
20 mM0.2030 mL1.0150 mL2.0300 mL10.1502 mL
50 mM0.0812 mL0.4060 mL0.8120 mL4.0601 mL
100 mM0.0406 mL0.2030 mL0.4060 mL2.0300 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Nefiracetam | purchase Nefiracetam | Nefiracetam cost | order Nefiracetam | Nefiracetam chemical structure | Nefiracetam in vivo | Nefiracetam in vitro | Nefiracetam formula | Nefiracetam molecular weight